Table 1 Study characteristics of the UK Biobank validation dataset.
Baseline characteristic | UK Biobank N = 395,393 | Male N = 180,653 (45.7%) | Female N = 214,740 (54.3%) |
|---|---|---|---|
Age, years [mean (sd)] | 56.9 (8.0) | 57.1 (8.1) | 56.7 (7.9) |
Current smoker, N (%) | 39,804 (10.0%) | 21,261 (11.8%) | 18,543 (8.6%) |
Systolic blood pressure, mm Hg [mean (sd)] (adjusted for BP medication) | 143.3 (21.7) | 146.9 (20.4) | 140.2 (22.2) |
Diabetes diagnosed by doctor, N (%) | 18,675 (4.7%) | 11,449 (6.3%) | 7226 (3.4%) |
Hypertension, N (%) | 211,069 (53.4%) | 110,540 (61.2%) | 100,529 (46.8%) |
Family history of stroke, 1st degree relative, N (%) | 104,831 (26.5%) | 45,569 (25.2%) | 59,262 (27.6%) |
High cholesterol, N (%) | 53,141 (13.4%) | 30,670 (17.0%) | 22,471 (10.5%) |
Prevalent stroke events, N (%), any stroke before age 75 | 4543 (1.1%) | 2679 (1.5%) | 1864 (0.9%) |
Prevalent stroke events, N (%), ischaemic stroke before age 75 | 1152 (0.3%) | 787 (0.4%) | 365 (0.2%) |
Incident stroke events, N (%), any stroke before age 75 | 2607 (0.7%) | 1531 (0.8%) | 1076 (0.5%) |
Incident stroke events, N (%), ischaemic stroke before age 75 | 1923 (0.5%) | 1207 (0.7%) | 716 (0.3%) |
On blood-pressure lowering medication, N (%) | 80,880 (20.5%) | 43,714 (24.2%) | 37,166 (17.3%) |
On lipid-lowering medication, N (%) | 66,739 (16.9%) | 40,164 (22.2%) | 26,575 (12.4%) |
Follow-up time, years [mean (sd)] | 6.3 (1.9) | 6.2 (2.1) | 6.4 (1.8) |
